Brokerages predict that Galapagos NV (NASDAQ:GLPG) will announce $115.36 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Galapagos’ earnings. The highest sales estimate is $172.72 million and the lowest is $58.00 million. The firm is scheduled to report its next earnings report on Thursday, March 24th.
On average, analysts expect that Galapagos will report full year sales of $549.41 million for the current fiscal year, with estimates ranging from $468.64 million to $597.59 million. For the next year, analysts anticipate that the business will post sales of $542.03 million, with estimates ranging from $259.84 million to $687.53 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Galapagos.
Galapagos (NASDAQ:GLPG) last posted its earnings results on Friday, November 5th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.67) by $0.50. Galapagos had a negative return on equity of 7.81% and a negative net margin of 36.28%. The firm had revenue of $75.69 million for the quarter, compared to analysts’ expectations of $95.17 million.
Shares of GLPG traded up $1.16 during mid-day trading on Thursday, hitting $49.62. 131,250 shares of the company’s stock traded hands, compared to its average volume of 281,026. Galapagos has a 1 year low of $47.87 and a 1 year high of $129.03. The business’s 50-day moving average price is $52.68 and its 200-day moving average price is $61.52.
Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in Galapagos by 1,217.6% in the second quarter. JPMorgan Chase & Co. now owns 448 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 414 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Galapagos by 476.0% during the second quarter. Quadrant Capital Group LLC now owns 576 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 476 shares in the last quarter. Atlas Capital Advisors LLC lifted its holdings in shares of Galapagos by 201.1% during the second quarter. Atlas Capital Advisors LLC now owns 1,048 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 700 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Galapagos during the second quarter valued at $72,000. Finally, Geneos Wealth Management Inc. bought a new position in shares of Galapagos during the first quarter valued at $127,000. 11.17% of the stock is currently owned by institutional investors and hedge funds.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Further Reading: How a Back-End Load Mutual Fund Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.